Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
1 hedge funds and large institutions have $2 invested in Virpax Pharmaceuticals, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 6 closing their positions.
86% less funds holding
Funds holding: 7 → 1 (-6)
100% less capital invested
Capital invested by funds: $34.9K → $2 (-$34.9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$26.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.88K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.4K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$130 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Osaic Holdings
Scottsdale,
Arizona
| $2 | – | – | – |
|
|
2
Millennium Management
New York
| – | -$26.5K | -22,075 | Closed |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| – | -$5.88K | -4,897 | Closed |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$2.4K | -2,000 | Closed |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| – | -$130 | -108 | Closed |
|
|
6
Bank of America
Charlotte,
North Carolina
| – | -$6 | -5 | Closed |
|
|
VWM
7
Vermillion Wealth Management
Rosemount,
Minnesota
| – | -$5 | -4 | Closed |
|
VRPX Hedge Fund Activity: Q2 2025 in Review
1 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q2 2025, worth a combined $2 — down 100% from $34.9K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VRPX and 0 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Millennium Management, exiting entirely with an estimated $26.5K sold.
- 1 institutional investor held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q2 2025, down from 7 in Q1 2025.
- Funds reported $2 of Virpax Pharmaceuticals, Inc. Common Stock stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q2 2025 and 6 closed out, a net change of -6 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q2 2025 was Millennium Management, an estimated $26.5K sold.
Based on aggregated 13F filings for Q2 2025.